pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
pharmadog news

Browse

1,049 stories matching this filter · ← front page

★ save view↓export CSV
rangeto
sort
recentoldestsourcealpha
source
STAT815Endpoints615BioPharma Dive237onclive165Fierce Biotech82BioSpace81raps32globenewswire health26fda press
therapy area
allOncology81Cardiology27Psychiatry & CNS21Vaccines17Immunology17Rare Disease12Hepatology
  • FDA approves Regeneron’s hearing loss gene therapy
    Otarmeni, now cleared to treat a rare, inherited kind of hearing loss, is the first gene therapy cleared under the FDA’s “national priority” voucher program and will be offered to eligible patients…
    BioPharma Dive · 3mo ago↗ source
  • FDA approves Regeneron's hearing loss gene therapy Otarmeni
    Regeneron has won the first-ever FDA approval for a gene therapy to treat a rare type of inherited hearing loss, and the company plans to offer the treatment for free in the US, though that ...
    Endpoints · 3mo ago↗ source
  • Substance use disorder biotech Tempero to close after earlier 'serious' safety event
    Tempero Bio, a drug developer that had big ambitions to shake up the treatment of substance use disorders, is winding down operations, Endpoints News has learned. The shutdown comes after a "seriou…
← prev
page 42 of 42
next →
21
fda recalls20
fda medwatch16
6
Hematology6
Pulmonology5
Infectious Disease4
Ophthalmology3
Dermatology2
Endpoints · 3mo ago
↗ source
  • Post-Hoc Live: MAHA, the new Trump CDC pick and RFK's vaccine agenda
    MAHA’s sway over HHS could face a fresh test now that President Trump has a new pick for CDC director: Erica Schwartz, a former deputy surgeon general. The position has been empty ...
    Endpoints · 3mo ago↗ source
  • Novartis' radioligand therapy Lutathera could soon face generic competition
    The radioligand field is on the cusp of a major competitive moment, as a rival looks to bring the first generic to a market that’s been dominated by Novartis. Radioligand therapy aims to bring the ...
    Endpoints · 3mo ago↗ source
  • Drugmaker AbbVie chooses North Carolina for $1.4B manufacturing campus
    The 185-acre site will be the company’s largest single investment to date, with a focus on small-volume parenteral products like vials and prefilled syringes.
    BioPharma Dive · 3mo ago↗ source
  • Roche, facing biosimilar threats, puts faith in new cancer and obesity drugs
    On a conference call, executives claimed that a closely watched breast cancer pill and portfolio of weight loss medicines could bank more than $9 billion annually.
    BioPharma Dive · 3mo ago↗ source
  • David Reese to retire from Amgen
    Longtime Amgen leader David Reese is retiring at the end of June, Amgen announced Wednesday evening. Reese, 63, currently serves as chief technology officer, a role he created at Amgen in 2023 ...
    Endpoints · 3mo ago↗ source
  • Sanofi posts upbeat sales as R&D pressure builds
    A string of research setbacks have left the pharmaceutical giant at a crossroads just as a new CEO is set to take over. But positive first-quarter earnings provided the company with a needed boost.
    BioPharma Dive · 3mo ago↗ source
  • The Godmother of Silicon Valley is helping launch an AI healthcare residency program
    Esther Wojcicki wants to help healthcare startup co-founders get along. That might seem simple, but co-founder disagreements are a big contributor to startups falling apart, she said. She’s got the…
    Endpoints · 3mo ago↗ source
  • Novo's pill for kids; Altimmune’s $225M offering; Merck teams with Google Cloud
    Novo Nordisk’s GLP-1 pill works in kids with diabetes: Type 2 diabetes patients aged 10 to 17 who took Rybelsus for about six months had a statistically significant 0.83% cut in their blood sugar l…
    Endpoints · 3mo ago↗ source
  • Amneal to buy a biosimilar company; Samsung Bio workers protest
    Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals to acquire biosimilar maker for $375M upfront: The generics and specialty drugmaker is s…
    Endpoints · 3mo ago↗ source
  • Endpoints wins Neal Awards for Trump and gene editing coverage, JPM event
    Endpoints News was recognized with three 2026 Neal Awards for its coverage of the drug industry's relationship with the Trump administration, a three-part series on the future of CRISPR gene editin…
    Endpoints · 3mo ago↗ source
  • Gravity Rail raises $2.75M from Redesign Health for AI patient communication
    A startup that helps healthcare providers handle calls, texts and follow-ups with patients using AI has raised seed funding, Endpoints News learned exclusively. Gravity Rail handles the process of…
    Endpoints · 3mo ago↗ source
  • Roche says its investigational breast cancer pill could outsell Herceptin
    Roche still has high sales hopes for its breast cancer pill giredestrant despite the drug’s failure in a first-line trial earlier this year. CEO Thomas Schinecker said Thursday that the drug could ...
    Endpoints · 3mo ago↗ source
  • Sanofi defends Garijo appointment, says it is 'fully committed' to immunology
    Sanofi’s first-quarter earnings call with the media on Thursday was an exercise in redirecting the narrative before its new CEO steps in next week. CFO François-Xavier Roger defended the company’s…
    Endpoints · 3mo ago↗ source
  • OpenAI's head of health lays out the AI giant’s healthcare ambitions
    OpenAI is launching ChatGPT for Clinicians, a free tool for doctors, nurse practitioners, physician assistants and pharmacists. It’s the latest product the AI giant has launched within healthcare,…
    Endpoints · 3mo ago↗ source
  • AbbVie's $1.4B North Carolina manufacturing site to finish during Trump's term
    AbbVie has provided new details about its $100 billion pledge to the US, budgeting $1.4 billion for its first manufacturing campus in North Carolina. Construction of the 185-acre campus in Durham,…
    Endpoints · 3mo ago↗ source
  • BridgeBio’s oncology spinoff swaps out CEOs as it seeks to accelerate KRAS work
    BridgeBio Oncology Therapeutics is replacing CEO Eli Wallace, putting its CSO Pedro Beltran in the role, and making board member Neil Kumar executive chairman. The changes come as there’s been grow…
    Endpoints · 3mo ago↗ source
  • Pharma-backed petition calls on FDA to reform release of drug rejection letters
    The FDA for the first time is facing pharma-backed criticism of its new practice of publicly releasing partially redacted drug rejection letters. The law firm Covington & Burling, on behalf of an u…
    Endpoints · 3mo ago↗ source
  • Revolution drug shows promise in early pancreatic cancer
    The findings build on data suggesting Revolution’s therapy could upend treatment for a notoriously tough-to-treat tumor and generate billions in sales.
    BioPharma Dive · 3mo ago↗ source
  • Moderna, after losing US funding, rebounds to start mRNA bird flu vaccine trial
    A program that got caught up in HHS’ decision to abandon mRNA research was revived by a public-private coalition and is now beginning a large, late-stage test that could support a future approval.
    BioPharma Dive · 3mo ago↗ source
  • Merck adds to pharma’s AI push; Roche details MS drug results
    Merck is making a $1 billion investment in a deal with Google Cloud. Elsewhere, Roche pitched its case for a closely watched multiple sclerosis pill and Arcus and Gilead are ending a yearslong alli…
    BioPharma Dive · 3mo ago↗ source
  • An ‘AI scientist’ can tackle drug R&D. What does that mean for pharma?
    A new tool is giving researchers a “data center full of genius Ph.D. students in their pocket.”
    BioPharma Dive · 3mo ago↗ source